Bladder Cancer Expert Debates VL

TURBT Quality Indicators and Access Issues in the United Kingdom - Param Mariappan & Prashant Patel

Details
Param Mariappan, MBBS, FRCS(Urol), PhD, and Prashant Patel, MBBS, MS, FRCSEd, FRCSEd (Urol), PhD, join Ashish Kamat, MD, MBBS, and discuss transurethral resection of bladder tumor (TURBT). Dr. Mariappan begins by explaining the importance of quality indicators for TURBT. He emphasizes the importance of having a comprehensive checklist of quality indicators. Dr. Patel discusses the current challeng...

Molecular Subtyping of Bladder Cancer: Ready for Prime Time? - Eva Comperat & Hikmat Al-Ahmadie

Details
Eva Comperat and Hikmat Al-Ahmadie, MD, join Ashish Kamat, MD, MBBS to challenge the use of immunohistochemistry, or traditional pathology, versus molecular subtyping in bladder cancer. Dr. Comperat discusses immunohistochemistry, explaining it is more precise, and because it is standardized and more widely used than molecular subtyping, it remains the gold standard. Dr. Al-Ahmadie continues by de...

T2 Muscle-Invasive Bladder Cancer: Tri-Modality Therapy (TMT) versus Radical Cystectomy - Stephen Williams & Nick James

Details
In this conversation moderated by Ashish Kamat, the use of trimodal therapy versus radical cystectomy for treating T2 bladder cancer is debated by Stephen Williams and Nick James. During the debate, Dr. James speaks in favor of trimodal therapy for a hypothetical patient with muscle-invasive bladder cancer, focusing on case studies and the potential for benefit of combining chemotherapeutic option...

Neoadjuvant Immune-Checkpoint Inhibition Vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer (MIBC) - Andrea Necchi and Petros Grivas

Details
Ashish Kamat, MD, MBBS moderates a debate between Andrea Necchi, MD, and Petros Grivas, MD, PhD, on current and emerging treatment options for muscle-invasive bladder cancer. Dr. Necchi argues on the side of immunotherapy before radical cystectomy, reviewing the PURE-01 study of pembrolizumab and the similarly-designed ABACUS study of atezolizumab. He notes that these studies reveal the need for b...

Management of High-Grade T1 Bladder Cancer: Cystectomy versus BCG - Bernard Bochner & Paolo Gontero

Details
Ashish Kamat welcomes leading bladder cancer experts Paolo Gontero and Bernard Bochner to engage in a debate considering a hypothetical patient with nonmuscle invasive high-grade T1 disease. Dr. Bochner starts by addressing different treatment options for patients presenting with T1 disease while acknowledging that T1 disease is a spectrum and can be variably invasive. He discusses BCG as a treatm...

Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin

Details
Alison Birtle and Surena Matin join Ashish Kamat for an educational session on the highly debated question of “should we use neoadjuvant or adjuvant therapy when it comes to upper tract urothelial carcinoma?” Dr. Birtle is the Chief Investigator of the POUT study and presents the side of adjuvant chemotherapy for the standard of care in patients with upper tract urothelial carcinoma. Dr. Matin pre...

Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua

Details
In this discussion, Ashish Kamat moderates a debate between Sia Daneshmand and Trinity Bivalacqua comparing the benefits of enhanced cystoscopy with blue light cystoscopy in TURBT to the benefits of perioperative chemotherapy following TURBT. Dr. Daneshmand discusses the role of blue light cystoscopy (BLC ®) in TURBT that there is an improvement in detecting tumors and their respective margins dur...

A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black

Details
Joining Ashish Kamat are Arjun Balar and Peter Black to consider the use of nadofaragene firadenovec versus pembrolizumab for a patient with BCG unresponsive carcinoma in situ in the bladder where the patient is ineligible for a cystectomy. Dr. Balar speaks to the side of systemic checkpoint blockade, discussing the early trials using systemic checkpoint blockade and highlighting results of the KE...